312 related articles for article (PubMed ID: 15967839)
1. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
2. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
3. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
4. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
6. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
7. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
10. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
11. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
12. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong FS; Mitchell CA; Zantomio D
Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
[No Abstract] [Full Text] [Related]
13. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Meng HT; Li Y; Jin J; Qian WB; Yang CM
Ann Hematol; 2007 Mar; 86(3):231-2. PubMed ID: 17123082
[No Abstract] [Full Text] [Related]
14. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
16. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
17. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
18. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Rosti G; Martinelli G; Baccarani M
Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
[No Abstract] [Full Text] [Related]
19. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Atallah E; Kantarjian H; Cortes J
Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
[No Abstract] [Full Text] [Related]
20. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
